Key Links:
By Topic:
Search:
ICAAC 2005: Index of Coverage
Special Features
- What Is the Most Important HIV Development of 2005? (December 19, 2005)
Researchers, physicians and other attendees of ICAAC 2005 are asked for their views; here's what they had to say.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Antiretrovirals in Development
- BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - New Protease Inhibitor Brecanavir Shown to Be Safe and Effective in Small Study (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Complications of HIV/HAART
- More Questions Than Answers Regarding High Hepatic Event Rates Among Thai Patients in 2NN Study (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Benefit of Rosiglitazone or Metformin for Lipodystrophy Still Unclear (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Ritonavir-Boosted Tipranavir Increases ALT and AST Levels in HIV/Hepatitis-Coinfected Patients (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Spanish Study Finds Association Between Long-Term Treatment With Tenofovir and Kidney Toxicity Still Unclear (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Study Finds That Select NRTIs Do Not Harm Kidneys (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Tenofovir Proves Safe for Kidneys After Three Years of Use (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Twice-Daily Massage Can Reduce Papule Formation Among HIV-Infected Patients Receiving Poly-L-Lactic Acid Injections (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Drug Resistance
- Analyzing the Pattern of Resistance Mutation Emergence of a Failing Abacavir + Lamivudine + Tenofovir Regimen Reveals a Possible Compensatory Mutation (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Researchers Uncover Possible Alternative Pathway to Tenofovir Resistance (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Small Study Suggests Genotypic Resistance Tests Maintain Accuracy Even When Viral Load Is Below 1,000 (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Treatment Strategies
- Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Better Adherence With Once-Daily Versus Twice-Daily Lopinavir/Ritonavir: New Tablet Formulation Has Improved GI Tolerability (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Dual-Boosted Protease Inhibitor Regimen Shows Promise, but How Will It Be Used? (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Quadruple-NRTI Regimen No More Desirable Than Triple-NRTI Regimen in Treatment-Naive Patients, Study Finds (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Severe Events Unrelated to AIDS or Antiretrovirals Were Most Common in Early HAART Patients (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Two NRTIs or Three? Makes No Difference When Taken With Efavirenz, ACTG 5095 Finds (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
  |